DBV Technologies S.A.
DBVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001613780
In the last 90 days, DBV Technologies S.A. insiders filed 0 open-market purchases and 1 sale; 78 institutions reported holding it in 13F filings for Q2 2026, worth $345.7M in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesDBVTF
Q3 2021 vs. Q2 2021
How the institutions holding DBV Technologies S.A. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 48 | 51 | +3 |
| Shares | 36.6M | 36.4M | −194.6K (−0.5%) |
| Value | $201.5M | $179.8M | −$21.7M (−10.8%) |
New holders (6)
Institutions that held DBV Technologies S.A. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 111,724 | $547.0K | 0.00% |
| The PNC Financial Services Group, Inc. | 7,343 | $36.0K | 0.00% |
| Meridian Wealth Partners, LLC | 2,000 | $10.0K | 0.00% |
| Lindbrook Capital, LLC | 866 | $4.00K | 0.00% |
| Barclays PLC | 37 | $0 | 0.00% |
| Harbour Investments, Inc. | 94 | $0 | 0.00% |
Sold out (3)
Institutions that held DBV Technologies S.A. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Arrowstreet Capital, Limited Partnership | 51,800 | $283.0K |
| Marshall Wace North America L.P. | 13,880 | $76.0K |
| Tower Research Capital LLC (TRC) | 1,893 | $10.0K |